Skip to main content

Table 2 Baseline characteristics of individual studies included in review

From: One- and two-stage surgical revision of infected elbow prostheses following total joint replacement: a systematic review

Lead Author, Publication Date (Reference No.) Location Year of study Mean/median age (years) % male Indication for index TER Mean/median interval between stages (months) Common infecting organism Common IV ATBs given after revision surgery Follow up Mean/median (years) No. of re-infections No. of deaths No. of non-infection related adverse events No. of participants No. of elbows joints Quality score
One-stage
 Gille, 2006 [23] Germany 1978–1999 62.7 0.0 RA (100%) NA S. aureus Flucloxacillin 6.8 1 0 1 5 6 10
 Spormann, 2012 [24] Switzerland 1994–2007* 67.0 0.0 NR NA CNSA Oral ciprofloxacin/rifampin given 4.0 0 NR NR 1 1 11
Two-stage
 Yamaguchi, 1998 [12] USA 1981–1994 53.8 40.0 RA (80%); OA (20%) 3.7 S. aureus; S. epidermidis None given 4.1 1 0 1 5 5 11
 Yamaguchi, 1999 [22] USA 1981–1994 59.7 28.6 RA (85.7%); PTA (14.3%) NR S. aureus; S. epidermidis NR 4.3 1 0 4 7 7 10
 Achermann, 2011 [13] Switzerland 1994–2007 NR NR RA; OA 5.5 NR Flucloxacillin/rifampin NR 0 NR NR 2 2 9
 Spormann, 2012 [24] Switzerland 1994–2007 54.5 100 RA; PTA; OA; psoriasis NR CNSA Flucloxacillin/rifampin 6.4 0 NR NR 4 4 11
 Peach, 2013 [25] UK 1998–2010 65.0 30.3 RA; fracture; OA; PTA 9.0 CNSA Cefuroxime 4.3 4 0 2 33 34 11
 Rudge, 2018 [26] UK 2009–2014 64.7 31.6 RA; PTA; fracture; OA 6.4 S. aureus Tazocin, teicoplanin, amikacin 3.0 3 0 9 19 19 10
 Zmistowski, 2018 [27] USA 2001–2016 NR NR PTA; RA; Unknown; fracture 5.7 NR NR 3.0 3 0 3 16 16 10
  1. ATBs Antibiotics, CNSA Coagulase negative Staphylococcus aureus, IV Intravenous, NA Not applicable, NR Not reported, OA Osteoarthritis, PTA Post-traumatic arthritis, RA Rheumatoid arthritis, S Staphylococcus; *, for all participants included in the series